Vogelsang Ingo
Boston University, CAS Economics, 270 Bay State Road, Boston, MA 02215 USA,
J Ment Health Policy Econ. 1999 Mar 1;2(1):29-41. doi: 10.1002/(sici)1099-176x(199903)2:1<29::aid-mhp35>3.0.co;2-a.
Recent empirical research has found behavioral health carve-outs in the US to reduce costs immediately and considerably, compared to indemnity insurance and HMOs. Carve-outs have quickly captured a large part of the organized market in US behavioral health. At the same time, market concentration has increased significantly. METHODS: The current paper uses concepts and results from the industrial organization and transaction cost literature to explain (i) why carve-outs hold cost advantages over other institutional arrangements, (ii) why these hold in particular for behavioral health and (iii) why this did not happen earlier. RESULTS: The main explanatory variables relate to economies of scale, the avoidance of diseconomies of scope, and the avoidance of personal relationships. The sometimes surprising lack of explicit risk-taking by carve-outs and of explicit cost-reducing incentives in carve-out contracts are more than overcome by incentives created from gaining large contracts. The specific advantages of carve-outs in behavioral health derive from a combination of lack of economies of scope with other health services, lack of economies of scale in provision of behavioral health and presence of economies of scale in management. It is conjectured that behavioral health carve-outs have benefited from biomedical innovations that changed the direction of treatments, from computerization that enables large-scale standardized management and from financial pressures on the behavioral health sector. DISCUSSION: The empirical basis for the current study is a number of case studies and the rapid penetration of mental health carve-outs in the US. Cost reductions caused by such carve-outs appear to be quite robust. Explaining cost reductions from institutional changes has to start with the question of why the old institution did not implement the same or similar changes. We have emphasized reasons why such changes were not feasible under indemnity insurance and HMOs. Nevertheless, we have not been able to evaluate quality changes that might have accompanied those cost reductions. IMPLICATIONS FOR HEALTH POLICY: While further cost reductions may follow a logistic curve, which simply flattens out, there are developments, regulatory and legal in particular, that could lead to a regression of carve-out costs towards those under other institutional arrangements. Thus, the main health policy questions arising from this study are to what extent the freedom of carve-outs to hold costs down should be upheld and to what extent the cost reductions should be used to increase behavioral health coverage. IMPLICATIONS FOR FURTHER RESEARCH: I see three main avenues for further research. The first is to find more empirical evidence for the hypotheses developed in this paper. The second is to look for other countries and other areas of health care with characteristics that would lend themselves to the application of carve-outs. The third is to analyze the quality aspect of carve-outs. The empirical question here is "What has been the effect of carve-outs on the quality of behavioral health care in the US?". The theoretical question is "What are the incentives of the sponsors of carve-out plans and of the carve-out management to assure quality provision of care?".
近期的实证研究发现,与赔偿保险和健康维护组织(HMO)相比,美国的行为健康独立核算部门能立即且大幅降低成本。独立核算部门迅速占据了美国行为健康有组织市场的很大一部分。与此同时,市场集中度显著提高。
本文运用产业组织和交易成本文献中的概念及结果来解释:(i)为何独立核算部门比其他制度安排具有成本优势;(ii)为何这些优势尤其体现在行为健康领域;(iii)为何这种情况没有更早出现。
主要解释变量涉及规模经济、范围不经济的避免以及人际关系的避免。独立核算部门有时令人惊讶地缺乏明确的风险承担以及独立核算合同中缺乏明确的成本降低激励措施,但通过获得大合同所产生的激励措施足以弥补这些不足。行为健康独立核算部门的特定优势源于与其他健康服务缺乏范围经济、行为健康服务提供中缺乏规模经济以及管理中存在规模经济的综合作用。据推测,行为健康独立核算部门受益于改变治疗方向的生物医学创新、实现大规模标准化管理的计算机化以及行为健康部门的财务压力。
本研究的实证基础是一些案例研究以及美国心理健康独立核算部门的迅速渗透。此类独立核算部门带来的成本降低似乎相当可观。从制度变革角度解释成本降低必须从旧制度为何未实施相同或类似变革这一问题入手。我们强调了在赔偿保险和健康维护组织下此类变革不可行的原因。然而,我们未能评估可能伴随这些成本降低的质量变化。
虽然进一步的成本降低可能遵循一条逐渐趋于平缓的逻辑曲线,但存在一些发展情况,特别是监管和法律方面的情况,可能导致独立核算部门的成本回归到其他制度安排下的成本水平。因此,本研究引发的主要健康政策问题是,应在多大程度上维护独立核算部门控制成本的自由,以及应在多大程度上利用成本降低来扩大行为健康覆盖范围。
我认为有三个主要的进一步研究途径。一是为本文提出的假设寻找更多实证证据。二是寻找其他具有适合应用独立核算部门特点的国家和其他医疗保健领域。三是分析独立核算部门的质量方面。这里的实证问题是“美国独立核算部门对行为健康护理质量产生了什么影响?”理论问题是“独立核算计划的发起者和独立核算管理部门确保提供高质量护理的激励因素是什么?”